Theramex news - Theramex

This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.

View your own country’s website

8 March 2023

Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS®▼ in the European Economic Area, the United Kingdom, Australia and Brazil

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

14 April 2022

Theramex UK Stock Update

28 March 2022

A consortium of Carlyle and PAI Partners to acquire Theramex from CVC Funds

21 March 2022

Theramex supports the IOF SCOPE 2021 recommendations and call to action to address the inequalities in Osteoporosis care across Europe

28 February 2022

Theramex Statement: Russia-Ukraine Crisis

Load more

Read more about Theramex